Comparative Pharmacology
Head-to-head clinical analysis: HIPPURAN I 131 versus PYROLITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HIPPURAN I 131 versus PYROLITE.
HIPPURAN I 131 vs PYROLITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HIPPURAN I 131 (iodohippurate sodium I-131) is a radiopharmaceutical that is actively transported by the renal tubules, allowing dynamic imaging of renal function. The I-131 isotope emits beta and gamma radiation, enabling scintigraphic visualization of renal perfusion and excretion.
Pyrolite is not a recognized pharmaceutical drug. No mechanism of action data available.
1 mCi (37 MBq) intravenously for adults; dose adjusted based on clinical indication and imaging protocol.
1000 mg orally every 8 hours for 7 days.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in patients with normal renal function; prolonged in renal impairment, up to 20-40 hours in severe impairment.
Terminal half-life: 4.5 hours (range 3.8–5.2). Clinical context: Eliminated rapidly; no accumulation with q6h dosing; dose adjustment needed in CrCl <30 mL/min.
Renal: >95% excreted unchanged in urine via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Renal: 70% unchanged; Fecal: 20% as metabolites; Biliary: 10% as conjugates.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical